MYOV News and Press, Myovant Sciences Ltd. From 05/21/21

CHMP opinion recommending approval based on data from the Phase 3 LIBERTY program in women with uterine fibroids Gedeon Richter will commercialize RYEQO for uterine fibroids, if approved, in Europe Relugolix combination tablet for uterine fibroids is also under U.S. FD...

Myovant Sciences (MYOV) has lost ~7.1% in the pre-market after announcing that the FDA has placed a partial clinical hold on its SERENE study (MVT-601-050).The FDA decision was pending an amendment to the study protocol “to add bone mineral density monitoring,” the com...

Image source: The Motley Fool. Myovant Sciences Ltd. (NYSE: MYOV) Q4 2020 Earnings Call May 11, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Myovant Sciences Ltd. (MYOV) Q4 2020 Earnings Call Transcript

Myovant Sciences Ltd. (MYOV) Q4 2020 Earnings Conference Call May 11, 2021 8:30 A.M. ET Company Participants Ryan Crowe - Vice President of Investor Relations Dave Marek - Chief Executive Officer Lauren Merendino - Chief Commercial Officer Frank Karbe - President and Chief Financial Officer C...

The following slide deck was published by Myovant Sciences Ltd. in conjunction with their 2021 Q4 earnings call. For further details see: Myovant Sciences Ltd. 2021 Q4 - Results - Earnings Call Presentation

Myovant Sciences (MYOV): FQ4 GAAP EPS of -$0.89 beats by $0.11.Revenue of $24.6M misses by $0.03M.Shares +4.5% PM.Press Release For further details see: Myovant Sciences EPS beats by $0.11, misses on revenue

Fourth fiscal quarter 2020 total revenues of $24.6 million; net product revenue from sales of ORGOVYX in the U.S. of $3.6 million FDA review of New Drug Application for relugolix combination tablet for uterine fibroids remains on track for a decision by June 1, 2021 target actio...

The FDA is currently reviewing the relugolix combination therapy for symptoms of Uterine Fibroids and set a PDUFA date on 6/1/2021. Myovant is currently successfully launching its first approved product ORGOVYX in partnership with Pfizer. Relugolix has the potential to become the ...

BASEL, Switzerland, May 04, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its fourth fiscal...

SERENE is a Phase 3 single-arm, open-label study evaluating the contraceptive efficacy of investigational relugolix combination tablet in sexually active, healthy women ages 18-35 years Contraceptive potential of relugolix combination tablet supported by prior Phase 1 study that...